New tailored therapy offers hope for older hodgkin lymphoma patients
NCT ID NCT05404945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment plan that adjusts chemotherapy based on a patient's fitness level for adults aged 60 and older with untreated classical Hodgkin lymphoma. All participants receive the immunotherapy drug pembrolizumab plus another targeted drug, then a PET scan and fitness test decide if they get standard, reduced, or no chemotherapy. The goal is to improve remission rates while reducing side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08902-2681, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Virginia
Charlottesville, Virginia, 22911, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?
- Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Engineered donor cells take on lymphoma in early trial